In-Depth Examination Of 6 Analyst Recommendations For Evolent Health
Portfolio Pulse from Benzinga Insights
Evolent Health (NYSE:EVH) has been the subject of 6 analyst recommendations in the last three months, showing a mix of bullish and somewhat bullish sentiments with no bearish views. The average 12-month price target is $44.00, down from $45.50, with targets ranging from $38.00 to $52.00. Analyst actions include ratings adjustments and price target changes by firms such as Citigroup, Canaccord Genuity, JP Morgan, Oppenheimer, and JMP Securities. Evolent Health, a company engaged in healthcare delivery and payment, has shown a solid revenue growth rate of 45.4% and has a market capitalization above industry averages, despite a high debt-to-equity ratio.
April 22, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolent Health has received mixed analyst ratings but remains predominantly bullish with a slight decrease in the average price target. The company's strong revenue growth and market position are positive, but its high debt ratio poses a risk.
The bullish and somewhat bullish ratings from analysts, combined with the company's solid revenue growth and strong market presence, suggest a positive short-term impact on EVH's stock price. However, the slight decrease in the average price target and the company's high debt-to-equity ratio introduce caution, potentially moderating the stock's upward momentum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100